DelveInsight’s “Pancreatic Cancer Pipeline Insight 2026” report provides comprehensive insights about 170+ companies and 200+ pipeline drugs in Pthe ancreatic Cancer pipeline landscape. It covers the Pancreatic Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pancreatic Cancer Pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download DelveInsight’s comprehensive Pancreatic Cancer Pipeline Report @ https://www.delveinsight.com/sample-request/pancreatic-cancer-pipeline-insight
Key Takeaways from the Pancreatic Cancer Pipeline Report
Stay ahead with the most recent pipeline outlook for Pancreatic Cancer @ Pancreatic Cancer Treatment Drugs
Pancreatic cancer Overview
Pancreatic cancer is a malignant neoplasm that arises primarily from the ductal epithelial cells of the pancreas, most commonly presenting as pancreatic ductal adenocarcinoma. It is considered one of the most aggressive and lethal cancers, ranking among the leading causes of cancer-related mortality worldwide. The disease is characterized by poor prognosis, with reported 5-year survival rates generally ranging between 5% and 15%, reflecting its highly aggressive nature and late detection. Histologically, the majority of cases are adenocarcinomas, with tumors most frequently originating in the head of the pancreas, although they can also arise in the body and tail.
Pancreatic cancer Emerging Drugs
TQB2868 injection is a PD-1/TGF-β bifunctional fusion protein independently developed by Chia Tai Tianqing Pharmaceutical Group. It can block the PD-1/PD-L1 pathway and neutralize TGF-β in the tumor microenvironment, exhibiting dual effects of immune checkpoint inhibition and tumor microenvironment remodeling. The combined inhibition of PD-1 and TGF-β signaling can lead to a more effective anti-tumor immune response than inhibition of either pathway alone, thereby improving clinical benefits in anti-tumor treatment. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of pancreatic cancer.
Trabedersen, also referred as OT-101 is a novel antisense oligodeoxynucleotide (ODN). It is a synthetic 18-mer phosphorothioate oligodeoxynucleotide (S-ODN) complementary to the messenger ribonucleic acid (mRNA) of the human TGF-β2 gene. Cancers overexpress TGF-β, which suppresses host innate immune response to the cancers. Treatment with OT-101 lifts the TGF-β cloaking effect and allows innate or therapeutic immunity to attack and eliminate the cancers. The drug has showed favorable safety and long-term disease control in over half of the treated patients in PDAC. Currently, the drug is being evaluated in the Phase II/III stage of its development for the treatment of pancreatic cancer.
Antroquinonol is a small molecule NCE with demonstrated activities both in-vivo and in-vitro against a number of malignancies, infectious diseases and neuro-degenerative diseases. Antroquinonol inhibited Ras and Ras-related GTP-binding protein activation through inhibition of protein isoprenyl transferase activity, leading to activation of autophagy and associated mode of cell death in cancer cells. Additionally, it can be taken orally, providing a convenient treatment option for patients. Antroquinonol has gained recognition for its groundbreaking work in the field of cancer treatment. It has been granted Orphan Drug Designation (ODD) by the FDA for the treatment of Pancreatic Cancer. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of pancreatic cancer.
Nadunolimab (CAN04) is an Anti-IL1RAP antibody for treatment of various cancer types. Nadunolimab binds strongly to its target molecule IL1RAP, expressed on tumor cells from many types of cancer. Nadunolimab blocks the signaling of interleukin-1, alpha and beta, thereby limiting tumor development as well as working synergistically with chemotherapy and adding functionality through Antibody-Dependent Cellular Cytotoxicity (ADCC). In June 2025, the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to nadunolimab for for the treatment of patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC) with high expression levels of IL1RAP in combination with gemcitabine and nab-paclitaxel. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of pancreatic cancer.
MT-601 is a promising Multi-Tumor Associated Antigen (multiTAA)-specific T cell therapy developed by Marker Therapeutics for treating advanced or metastatic pancreatic cancer. It is a non-genetically modified therapy that targets six antigens ommonly expressed in pancreatic tumors. Unlike CAR-T therapy, MT-601 is a non-genetically modified T cell product. It targets multiple tumor-associated antigens, which may reduce the risk of immune evasion by the tumor. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of pancreatic cancer.
Fb-PMT (NP751) is a novel, potent thyrointegrin antagonist that has shown high effectiveness in preclinical studies for pancreatic cancer, reducing tumor weight and viability by over 90% in mice Fb-PMT works by targeting the thyrointegrin receptor, which is overexpressed on the surface of pancreatic cancer cells and dividing blood vessel cells, inducing anti-angiogenic and anticancer effects. Currently, the drug is being evaluated in the preclinical stage of its development for the treatment of pancreatic cancer.
Explore groundbreaking therapies and clinical trials in the Pancreatic Cancer Pipeline @ New Pancreatic Cancer Drugs
The Pancreatic Cancer Pipeline report provides insights into
Pancreatic Cancer Companies
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd., Oncotelic Inc., Golden Biotechnology Corp., Cantargia AB, Marker Therapeutics, Inc., NanoPharmaceuticals, Innovent Biologics/Takeda, Verastem, Inc., Autotelic Bio Inc., Oncolytics Biotech, Agenus Inc., ONO PHARMACEUTICAL CO., LTD., Merck Sharp & Dohme LLC., Akeso Biopharma Co., Ltd., ImmunityBio, Inc., NETRIS Pharma, Merck & Co., Inc., Nihon Medi-Physics Co., Ltd., FutureGen Biopharmaceutical (Beijing) Co., Ltd., Can-Fite Biopharma, and InxMed and others.
Pancreatic Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
Pancreatic Cancer Products have been categorized under various Molecule types such as
Learn about new drugs, pipeline developments, and key companies with DelveInsight’s @ Pancreatic Cancer Market Drivers and Barriers
Scope of the Pancreatic Cancer Pipeline Report
Which companies are leading the race in Pancreatic Cancer drug development? @ Pancreatic Cancer Emerging Drugs and Major Companies
Table of Contents
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432City: Las VegasState: https://www.delveinsight.com/report-store/pancreatic-cancer-pipeline-insightCountry: United StatesWebsite: https://www.delveinsight.com/report-store/pancreatic-cancer-pipeline-insight
